Loading...
01/09 22:04
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture: while there are positive elements such as decreased expenses and a cash runway into 2026, the net losses and lack of specific guidance in certain areas temper enthusiasm. The Q&A section reveals confidence in ongoing studies but lacks clarity in some responses. The absence of a market cap limits the assessment of stock reaction sensitivity. Given these factors, the overall sentiment remains neutral, with no strong catalysts to drive significant short-term stock movement.
Net Loss $8.6 million or $0.68 per share for Q2 2025, compared to $11.8 million or $2.03 per share for Q2 2024. The decrease was primarily due to lower employee-related costs, research, consulting, and clinical costs.
Research and Development Expenses $7.5 million for Q2 2025, compared to $10.3 million for Q2 2024. The decrease was primarily attributable to lower employee-related costs, research, consulting, and clinical costs.
Research and Development Expenses (6 months) $16 million for the 6 months ended June 30, 2025, compared to $19.9 million for the same period in 2024. The decrease was primarily attributable to lower employee-related costs, research, consulting, and clinical costs.
General and Administrative Expenses $3.5 million for Q2 2025, compared to $4.8 million for Q2 2024. The decrease was primarily attributable to lower employee-related and legal costs.
General and Administrative Expenses (6 months) $7.5 million for the 6 months ended June 30, 2025, compared to $9.7 million for the same period in 2024. The decrease was primarily attributable to lower employee-related and legal costs.
Cash and Cash Equivalents $10.1 million as of June 30, 2025. This amount, along with proceeds from July 2025 offerings, is expected to fund operations into Q1 2026.
TakeAim Lymphoma study: Progress in evaluating emavusertib in combination with ibrutinib for PCNSL patients. Targeting accelerated submissions in the U.S. and Europe after enrolling 30-40 additional patients.
Emavusertib in CLL and NHL: Exploring potential to improve treatment paradigm by combining emavusertib with BTK inhibitors. Proof-of-concept study for relapsed/refractory CLL to start by year-end.
Emavusertib in AML: Registrational study planned comparing emavusertib versus gilteritinib in relapsed/refractory AML. Emavusertib shows higher composite CR rate compared to gilteritinib.
Emavusertib in MDS: Potential combination with azacitidine to address unmet needs in high-risk MDS patients.
Triplet study in frontline AML: Phase I study ongoing with emavusertib, venetoclax, and azacitidine. Progress to be reported at ASH conference in December.
Financial performance: Net loss of $8.6M in Q2 2025, improved from $11.8M in Q2 2024. Decrease in R&D and G&A expenses contributed to reduced losses.
Cash position: $10.1M in cash and equivalents as of June 30, 2025, with additional $6M raised in July. Funding expected to last into Q1 2026.
Regulatory Approval Challenges: The company is relying on accelerated submissions to the FDA and EMA for its TakeAim Lymphoma study. Any delays or issues in regulatory approval could significantly impact the timeline and success of their drug development.
Enrollment Challenges: The company needs to enroll 30 to 40 additional patients for the TakeAim Lymphoma study within the next 12 to 18 months. Failure to meet this enrollment target could delay regulatory submissions and subsequent commercialization.
Market Competition: The company faces competition from existing treatments like gilteritinib for AML. The success of emavusertib depends on demonstrating superior efficacy and safety, which is not guaranteed.
Financial Constraints: The company reported a net loss of $8.6 million for Q2 2025 and has cash reserves of $10.1 million, which are expected to fund operations only until Q1 2026. This financial limitation could hinder ongoing and future research and development activities.
Clinical Trial Risks: The success of emavusertib in various studies, including its combination with other drugs, is not guaranteed. Any negative outcomes could impact the company's strategic objectives and market position.
Dependence on Key Studies: The company’s future success heavily depends on the outcomes of its ongoing studies, such as the TakeAim Lymphoma study and the registrational study for AML. Any setbacks in these studies could adversely affect its strategic plans.
TakeAim Lymphoma Study: Over the next 12 to 18 months, the company will focus on enrolling 30 to 40 additional patients needed for NDA and EMA submissions. The study aims to support accelerated submissions in both the U.S. and Europe.
Emavusertib Expansion: Plans to expand emavusertib into additional indications in CLL and NHL. A proof-of-concept study targeting 20 to 30 patients with relapsed/refractory CLL is expected to begin by year-end, with initial data anticipated in mid-2026.
AML Registrational Study: The company plans to conduct a registrational study comparing emavusertib versus gilteritinib in the relapsed/refractory AML setting.
High-Risk MDS: The company is exploring the combination of azacitidine with emavusertib to address unmet needs in high-risk MDS, following the failure of the VERONA study.
Triplet Study in Frontline AML: The company is evaluating different dosing regimens of emavusertib, venetoclax, and azacitidine in a Phase I study. Progress updates are expected at the ASH conference in December.
The selected topic was not discussed during the call.
The earnings call highlights several risks, including regulatory challenges, financial constraints, and competition. The company reported a net loss, though reduced compared to the previous year, and has limited cash reserves. The Q&A section reveals a lack of detailed guidance and an emphasis on securing additional capital, indicating financial strain. Despite some positive clinical updates, the overall sentiment leans negative due to financial and strategic uncertainties.
The earnings call presents a mixed picture: while there are positive elements such as decreased expenses and a cash runway into 2026, the net losses and lack of specific guidance in certain areas temper enthusiasm. The Q&A section reveals confidence in ongoing studies but lacks clarity in some responses. The absence of a market cap limits the assessment of stock reaction sensitivity. Given these factors, the overall sentiment remains neutral, with no strong catalysts to drive significant short-term stock movement.
The earnings call highlights several concerns: ongoing financial losses, limited cash reserves, and competitive pressures. Despite some positive developments in clinical trials, there are significant regulatory and clinical risks. The lack of a share repurchase program and vague management responses in the Q&A further contribute to uncertainty. These factors suggest a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
